Jazz Acquires Narcolepsy Hopeful DSP-0187 in Agreement With Sumitomo Pharma
DSP-0187, an orexin-2 receptor agonist, adds to Jazz’s portfolio of sleep disorder therapies, expanding it into a new medicine class. The molecule will be referred to as JZP441 by Jazz.
According to a recent announcement, Jazz Pharmaceuticals and Sumitomo Pharma have entered into an agreement to codevelop and cocommercialize Sumitomo’s investigational sleep disorder treatment, DSP-0187. The molecule will be referred to as JZP441 by Jazz.1
DSP-0187 is a potent and highly selective oral orexin-2 receptor agonist that Sumitomo has been developing. It is currently being assessed in a single-dose phase 1 study in narcolepsy (jRCT2071210103), conducted in Japan, that kicked off in November 2021. That study is evaluating the pharmacokinetics, safety, and tolerability in healthy volunteers.1,2 Jazz noted that it plans to rapidly advance DSP-0187’s development based on the findings.
The treatment has shown potential application as a therapy for narcolepsy, as well as idiopathic hypersomnia and other sleep disorders. DSP-0187 is initially expected to be evaluated in narcolepsy, according to Jazz.
Rob Iannone, MD, MSCE, executive vice president, global head of research and development, Jazz Pharmaceuticals, said in a statement that the agreement illustrates Jazz’s ability to identify compounds of promise as well as the company’s “corporate objective of making strategic, value-creating investments in our pipeline."
"Orexin agonism is an exciting area of sleep disorder research and an approach that may be complementary to oxybate therapy. We believe that DSP-0187 has the potential to advance the treatment of narcolepsy and other sleep disorders based on its profile," Iannone added in the statement.1 "As a leader in sleep medicine, we are committed to delivering innovative therapies to people who are living with debilitating sleep disorders. We look forward to leveraging our expertise in sleep disorders to rapidly advance this promising therapy into clinical trials in the US and Europe.”
WATCH NOW:
Orexins, neuropeptides have a role in sleep and wakefulness regulation, are a class with a few recently FDA-approved members for the treatment of insomnia. Notably, in late 2019, the FDA
This will expand Jazz’s portfolio into the orexin class. As of now, the company’s list of approved agents includes a number of therapies for sleep disorders, such as its combination calcium, magnesium, potassium, and sodium oxybates, also known as
In early January 2022, Jazz
Patients then entered the double-blind randomized withdrawal period (DBRWP), where they received either the optimized dose or placebo for 2 weeks and were evaluated on changes in ESS scores beginning from the end of the stable dose period (SDP). During the DBRWP, ESS scores increased (representing a status worsening) in participants randomly assigned to placebo but remained stable in those assigned to JZP-258 (least squares mean difference: –6.5 [95% CI, –8.0 to –5.0]; P <.0001).7
Under the terms of this agreement with Sumitomo, the company will receive an upfront payment of $50 million, and will retain its commercialization and development rights in the Asia and Pacific territories, as well as Japan and China. Jazz, on the other hand, has licensed those rights in the United States, Europe, and other associated territories.1
"DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist, which is a novel small molecule compound originally created by Sumitomo Pharma by utilizing our advanced expertise in drug discovery for central nervous system disorders. We are pleased to partner with Jazz on DSP-0187 given their strong track record of development success and commercial execution in sleep disorders and long-term commitment to advancing therapies to improve the lives of people with sleep disorders," Toru Kimura, representative director and executive vice president, Sumitomo Pharma, said in a statement.1 "Jazz's accomplishments in sleep medicine make the company an ideal partner for us as DSP-0187 enters its next phase of development."
REFERENCES
1. Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist. News release. Jazz Pharmaceuticals. May 4, 2022. Accessed May 5, 2022. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-sumitomo-pharma-announce-exclusive-license-agreement-to-develop-and-commercialize-dsp-0187-a-potent-highly-selective-oral-orexin-2-receptor-agonist-301537690.html
2. Development Pipeline. Sumitomo Pharma website. Updated January 31, 2022. Accessed May 5, 2022. https://www.sumitomo-pharma.com/rd/clinical/pipeline.html
3. US FDA approved Eisai’s Dayvigo (lemborexant) for the treatment of insomnia in adult patients. News release. Eisai. December 23, 2019. Accessed May 5, 2022. https://eisai.mediaroom.com/2019-12-23-U-S-FDA-Approves-Eisais-DAYVIGO-TM-lemborexant-for-the-Treatment-of-Insomnia-in-Adult-Patients
4. Idorsia recieves US FDA approval of Quiviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed May 5, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/?s=85
5. George J. Idorsia's recently approved insomnia drug Quviviq hits the shelves. Philadelphia Business Journal. May 3, 2022. Accessed May 5, 2022. https://www.bizjournals.com/philadelphia/news/2022/05/03/insomnia-idorsia-quviviq-radnor-fda-switzerland.html
6. Lancet Neurology publishes positive, pivotal phase 3 data of Xywav (Calcium, magnesium, potassium, and sodium oxybates) oral solution for idiopathic hypersomnia. News release. Jazz Pharmaceuticals. January 5, 2022. Accessed May 5, 2022. https://www.prnewswire.com/news-releases/lancet-neurology-publishes-positive-pivotal-phase-3-data-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-301454171.html
7. Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomized withdrawal study. Lancet. 2022;21(1):53-65. doi:10.1016/S1474-4422(21)00368-9
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025